HEALTH TECHNOLOGY

Reliq Health Technologies, Inc. Signs Agreement with Cognizant to Expand Care Management Capabilities to Large Scale Clients

Reliq Health Technologies | January 06, 2022

Reliq Health Technologies Inc., a rapidly growing global healthcare technology company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, today announced an agreement with Cognizant to leverage Cognizant’s Care Management resources for future deployments of Reliq’s iUGO Care software to large scale clients. Cognizant provides services to 300+ health systems and over 347,000 care providers who together provide care to over 200 million lives globally.

“We are excited to be expanding our Care Management capabilities by leveraging Cognizant’s extensive resources, network, and experience in healthcare. Cognizant will be able to rapidly deploy a full suite of Care Management services to our largest new iUGO Care customers going forward. Reliq will continue to achieve the same or better profit margins on the Care Management component of our revenue as a result of this partnership but will be able to deploy our full-service solution (iUGO Care software plus Care Management services) to very large clients much faster. Our agreement with Cognizant will allow us to scale to new levels and provide even the largest healthcare organizations with confidence that we can meet the needs of their patient populations, no matter the size. This agreement will allow Reliq to access new opportunities to provide virtual care to much larger patient populations both within the US and globally.”

Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc.

Reliq’s iUGO Care solutions improve health outcomes, allow clinicians to provide high quality care to patients anytime, anywhere, and reduce the cost to the healthcare system, benefiting patients, clinicians and payers. Reliq’s iUGO Care and iUGO Home products are a critical component of a fully connected healthcare system. Reliq’s remote patient monitoring platform, iUGO Care, is currently used by a diverse array of healthcare organizations in the US. These include primary care practices, specialist practices, home care agencies, skilled nursing facilities, HIV clinics and hospice care agencies. The agreement with Cognizant will expand Reliq’s capabilities and extend its reach, allowing Reliq to provide its iUGO Care solution to managed care organizations, large health systems and health insurance providers.

About Cognizant
Cognizant engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we're improving everyday life. 

About Reliq Health
Reliq Health Technologies is a rapidly growing global healthcare technology that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq’s powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the WKN as A2AJTB.

Spotlight

Over the winter the NHS faces additional pressures. It is important to ensure that services and patient pathways are robust to deal with this increased demand. This Quick Guide is designed to provide practical information for dental providers and commissioners on what they can do to improve dental unscheduled care for patients over the winter period, and beyond. Throughout this document you will find practical tips, case studies and links to useful resources.


Other News
MEDICAL DEVICES

MedTech Company STENTiT Raises €1.8 million in Seed Round

STENTiT | April 25, 2022

STENTiT, a medical device company bringing a novel class of regenerative endovascular implants for the treatment of cardiovascular diseases, has closed a €1.8 million seed investment round. The funding facilitates further pre-clinical development and batch production of a regenerative stent (see video) for peripheral indications. The investment was made by Dutch investors NextGen Ventures, Brabant Development Agency and the Ten Cate Investment Company. STENTiT is an emerging player in the field of regenerative medical devices, offering a breakthrough solution for cardiovascular interventions by developing first-of-its-kind endovascular implants with regenerative capacity. Using a catheter-based approach, these devices provide the ability to restore arteries without the need for an invasive surgical intervention. The aim is to ultimately restore the affected blood vessel from the inside out to provide a lifelong solution. As a first target indication, the company wants to improve the treatment of critical limb ischemia. This progressive form of peripheral artery disease affects almost 5 million people in the EU and the US in which the blood flow to the foot is severely being compromised. Unfortunately, current treatment options are ineffective, resulting in amputation within 6 months in 40% of these patients. With the regenerative stent, blood flow to the foot will be maintained by securing vascular patency using temporary mechanical support and improving long-term efficacy by inducing vascular repair, thereby preventing thousands of amputations each year. "We are excited to receive the support of these esteemed Dutch early-stage investors. This financing round validates our vision to bring a novel class of implants that can rebuild the affected blood vessels. We are looking forward taking the next steps getting our regenerative stents ready for clinical trials. With our first product, we aim to treat millions of patients suffering from peripheral artery diseases, and save their limbs from amputation." Bart Sanders, CEO of STENTiT About STENTiT STENTiT is a medical device spin-off company from the Dutch Eindhoven University of Technology, focusing on the development of regenerative endovascular implants. These bioresorbable devices trigger a natural healing response by the circulating blood cells, in which the implant is being replaced by new vascular tissue to restore the artery from the inside-out. Since the establishment of the company, STENTiT has received broad international recognition and awards for its high-potential approach, covering world leading stages. As the company is currently going through the next translational phases, STENTiT is on its way to fulfill its ambition to become the new standard in endovascular treatment, providing a life-changing solution for millions of cardiovascular patients around the world.

Read More

FUTURE OF HEALTHCARE

Laborie Medical Technologies Acquires GI Supply

Laborie Medical Technologies | April 21, 2022

Leading diagnostic and therapeutic medical technology company, Laborie Medical Technologies Corp. announced that it has completed the acquisition of GI Supply, a leader in specialty endoscopy and paracentesis products for gastroenterologists, colorectal surgeons, and interventional radiologists. As part of the transaction, GI Supply and all its employees will be fully integrated into the Laborie business. "We've had the opportunity to work closely with the GI Supply team for two years and are delighted to welcome them into the Laborie family," said Michael Frazzette, President & CEO of Laborie Medical Technologies. "We look forward to working together in our mission to deliver innovative technologies that help preserve and restore human dignity. Gastroenterology will continue to be a core segment for Laborie and legacy GI Supply will lead our effort." In 2020, Laborie and Signet Healthcare Partners, a healthcare growth equity firm, signed an agreement to acquire GI Supply. The combined GI Supply and Laborie product portfolio and commercial capabilities enabled the organizations to reach a larger customer base and offer healthcare practitioners a broad portfolio of innovative gastroenterology products. "We are delighted with the growth and progress of GI Supply over the past several years. We thank Patricia Industries and Laborie for their partnership in helping to develop this business. The future is very bright for GI Supply as part of Laborie." Ashley Friedman, Managing Director at Signet Healthcare Partners Yuriy Prilutskiy, Head of North America at Patricia Industries, a part of Investor AB and majority owner of Laborie Medical Technologies added, "Patricia Industries is excited to continue investing in Laborie's long-term growth with this acquisition. We continue to support Laborie in its mission to provide patients and healthcare professionals with innovative and effective therapeutic and diagnostic technologies that preserve and restore human dignity." About Laborie Medical Technologies Headquartered in Portsmouth, New Hampshire, Laborie is a global medical technology company focused on Urology, Urogynecology, Gastroenterology, Obstetrics, Gynecology & Neonatal Health. We manufacture and deliver high-quality, high-impact diagnostic and therapeutic products that help clinicians and hospitals preserve and restore patient dignity. Clinicians and hospitals look to us as the market-leading experts in our business segments, and we support our products with a world-class Clinical Education & Information program. Laborie is a portfolio company of Patricia Industries. About GI Supply As a physician-founded company, we strive for deep clinical input into all that we do. GI Supply is broadening its portfolio with solutions that allow physicians to perform more-advanced procedures safely and efficiently. We help doctors do their jobs faster, safer and simpler. About Patricia Industries Patricia Industries, a part of Investor AB, invests in best-in-class companies with strong market positions, brands and corporate cultures within industries positioned for secular growth. We invest with an indefinite holding period and partner with great management teams to create value for people and society by building strong and sustainable businesses. About Investor AB Investor, founded by the Wallenberg family in 1916, is an engaged owner of high-quality, global companies. We have a long-term investment perspective. Through our board participation, industrial experience, global network and financial strength, we work continuously to support our companies to remain or become best-in-class. About Signet Healthcare Partners Signet Healthcare Partners is an established provider of growth capital to innovative healthcare companies. Signet invests in commercial-stage healthcare companies that are revenue generating or preparing for commercial launch. The firm invests primarily in pharmaceutical and medical device companies. As an active investor, Signet partners closely with its companies to build their value including facilitating activities between portfolio companies. During Signet's 24-year history, the firm has developed a strong reputation and track record of successful healthcare investments. Signet has raised funds with total capital commitments of over $500 million and has invested in more than 55 companies.

Read More

FUTURE OF HEALTHCARE

Omega Healthcare Acquires Reventics, a Physician Focused CDI and RCM Company

Omega Healthcare | March 09, 2022

Omega Healthcare, a leading healthcare management solutions partner supporting the broad healthcare ecosystem, today announced its acquisition of Reventics, aDenver, CObased company. Reventics is a clinical documentation improvement ("CDI") and revenue cycle management ("RCM") solutions provider that delivers Provider Engagement Solutions to enhance physician reimbursement and compliance, while improving clinical quality measures. This acquisition enables Omega Healthcare to expand its core coding and RCM offering by leveraging Reventics' proprietary cloud native platforms for CDI and RCM - RevCDI and RevMAX - along with expert clinical resources to drive improved outcomes for its clients. The transaction is part of Omega Healthcare's strategic growth plan to expand its existing CDI capabilities through technology-driven solutions, giving Omega exceptional scale and proficiency in this specialized competency. "Reventics brings to our organization clinical excellence, analytic capabilities, and new age technologies to complement Omega's existing technology and automation services. Not only is this a strategic fit that will benefit our clients, but we will be able to expand our CDI and RCM capabilities through this acquisition, while increasing our AI capabilities as well." Anurag Mehta, CEO of Omega Healthcare "We see our core values of "client first" approach reflected in Omega's own philosophy and are excited by how our clients could benefit from the larger enterprise and its extensive capabilities. We believe the client partnerships we currently enjoy will only be strengthened through this transaction." saysArnab Sen, CEO of Reventics. " "Omega is excited to welcome the Reventics team and is eagerly looking forward to creating enhanced value for its customers under the combined leadership" addedSumithra Gomatam, Executive Chair of Omega. Anurag Mehtawill continue to serve as the CEO of the combined entity. About Omega Healthcare Founded in 2003, Omega helps payers, providers, and pharmaceutical companies eliminate administrative burdens, accelerate cash flow, and reduce health management costs while enhancing patient care. The company streamlines medical billing, coding, and collections processes and provides virtual nursing services, including triage, care continuation, clinical documentation improvement, and re-admittance avoidance. Combining the largest medical coding staff in the world with proprietary technology, analytics, and automation capabilities, Omega provides the most comprehensive outsourced solutions in the industry and is ranked among the top revenue cycle management business process services by industry analysts. Backed by the Private Equity business within Goldman Sachs Asset Management and Everstone Group, Omega has more than 20,000 employees acrossthe United States,India,the Philippines. About Reventics Reventics is a physician-focusedclinical documentation improvement (CDI)andrevenue cycle management (RCM)company. The company is changing the way the industry thinks about CDI and RCM by placing the provider at the center of its solutions. From the AI that powers Reventics' products to its physician-led delivery approach, Reventics drives an unrelenting focus on clinicians, to improve their operational and financial outcomes. Reventics' approach is based on using itsto deliver Provider Engagement Solutions that enhance physician reimbursement and compliance while improving clinical quality measures.

Read More

FUTURE OF HEALTHCARE

SandboxAQ and Mount Sinai Health System Collaborate on Data Protection

Sandbox AQ | March 24, 2022

Sandbox AQ, an enterprise SaaS company leveraging quantum tech and AI, announced a collaboration with Mount Sinai Health System to launch Post-Quantum Cryptography solutions, a broad security technology solution to protect patient data against current and future cybersecurity threats. Sandbox has developed SaaS-based enterprise modules that incorporate the latest encryption protocol standards recently ratified by NIST (National Institute of Standards and Technology). Through Sandbox AQ, Mount Sinai Health System will incorporate PQC protocols into its network to provide increased security for millions of customers and their sensitive data. "Our collaboration with Sandbox AQ propels our security and technology strategies forward, enabling us to deliver advanced, secure cutting-edge products to our patients. Protecting patient data against cyber threats is incredibly important to us." Kristin Myers, Executive Vice President and Chief Information Officer at Mount Sinai Health System and Dean for Information Technology at Icahn School of Medicine at Mount Sinai "Quantum technology will quickly render today's RSA-based encryption obsolete, which is why it's imperative that we protect the world's sensitive data now against the next generation of cyberattacks," said Jack D. Hidary, CEO of Sandbox AQ, which officially launched today. "Mount Sinai is one of the first healthcare systems planning to implement PQC protocols into its health network to protect its customers and transform its business. We look forward to collaborating with them on this project." About SandboxAQ Sandbox AQ is an enterprise SaaS company delivering solutions at the nexus of quantum tech and AI. Based in Palo Alto, the inspiration for Sandbox AQ and some of the team originated at Alphabet Inc. in 2016. Sandbox AQ launched as an independent, venture-backed entity in 2022. About Mount Sinai Health System The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. We advance medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 7,300 primary and specialty care physicians; 13 free-standing joint-venture centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island; and more than 30 affiliated community health centers. The Mount Sinai Hospital is ranked in U.S. News & World Report's "Honor Roll" of the top 20 U.S. hospitals and among the top in the nation by specialty: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Urology, and Rehabilitation. Mount Sinai Kravis Children's Hospital is ranked in U.S. News & World Report's "Best Children's Hospitals" among the country's best in four out of 10 pediatric specialties. New York Eye and Ear Infirmary of Mount Sinai is ranked among the Top 20 nationally for ophthalmology. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and No. 14 in the nation for National Institutes of Health funding. Newsweek's "The World's Best Smart Hospitals" ranks The Mount Sinai Hospital as No. 1 in New York and top five globally, and Mount Sinai Morningside as top 20 globally, and "The World's Best Specialized Hospitals" ranks Mount Sinai Heart as No. 1 in New York and No. 4 globally and the Division of Gastroenterology as No. 3 globally, and the Division of Pulmonary Medicine as No. 6 globally.

Read More

Spotlight

Over the winter the NHS faces additional pressures. It is important to ensure that services and patient pathways are robust to deal with this increased demand. This Quick Guide is designed to provide practical information for dental providers and commissioners on what they can do to improve dental unscheduled care for patients over the winter period, and beyond. Throughout this document you will find practical tips, case studies and links to useful resources.

Resources